Aclaris Therapeutics Inc (ACRS)vsargenx NV ADR (ARGX)
ACRS
Aclaris Therapeutics Inc
$5.20
-2.26%
HEALTHCARE · Cap: $794.69M
ARGX
argenx NV ADR
$853.82
-2.15%
HEALTHCARE · Cap: $54.24B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 63429% more annual revenue ($5.32B vs $8.37M). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ACRS
Avoid30
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.7%
Fair Value
$7.02
Current Price
$5.20
$1.82 discount
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$853.82
$1573.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.2% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 180.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACRS
The strongest argument for ACRS centers on Revenue Growth, Debt/Equity. Revenue growth of 37.2% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bear Case : ACRS
The primary concerns for ACRS are EPS Growth, Market Cap, Profit Margin.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ACRS profiles as a hypergrowth stock while ARGX is a growth play — different risk/reward profiles.
ACRS carries more volatility with a beta of 0.77 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 30/100), backed by strong 32.3% margins and 59.3% revenue growth. ACRS offers better value entry with a 51.7% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclaris Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?